CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 1.4%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price traded down 1.4% during mid-day trading on Tuesday . The company traded as low as $55.47 and last traded at $56.28. 395,940 shares were traded during trading, a decline of 77% from the average session volume of 1,751,771 shares. The stock had previously closed at $57.06.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CRSP shares. Citigroup increased their price objective on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a "buy" rating in a research note on Thursday, April 18th. Barclays lifted their price target on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 22nd. Wells Fargo & Company upped their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 22nd. Mizuho lifted their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a research report on Wednesday, March 6th. Finally, Needham & Company LLC reissued a "buy" rating and set a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $76.29.

CRISPR Therapeutics Price Performance

The stock has a market cap of $4.71 billion, a P/E ratio of -28.36 and a beta of 1.80. The stock's 50-day moving average is $67.17 and its two-hundred day moving average is $64.60.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analysts' expectations of $148.72 million. The company's revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.41) EPS. On average, analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the company's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company's stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company's stock, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders sold 83,992 shares of company stock worth $6,132,335 over the last 90 days. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Tradewinds Capital Management LLC raised its holdings in shares of CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company's stock valued at $32,000 after acquiring an additional 600 shares in the last quarter. Blue Trust Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $32,000. Headlands Technologies LLC bought a new position in shares of CRISPR Therapeutics during the third quarter valued at approximately $34,000. Bourgeon Capital Management LLC increased its holdings in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock valued at $34,000 after buying an additional 500 shares during the period. Finally, Riggs Asset Managment Co. Inc. raised its stake in CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company's stock worth $34,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.